Lv1
94 积分 2021-10-14 加入
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
2个月前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
2个月前
已完结
Cytokine Release Syndrome: Trends with T Cell Engaging Bispecifics from a Systematic Review of Licensing Applications
2个月前
已完结
Cytokine Release Syndrome: Trends with T Cell Engaging Bispecifics from a Systematic Review of Licensing Applications
2个月前
已关闭
Abstract 1872: A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models
2个月前
已关闭
IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
2个月前
已完结
OX40 and OX40L Interaction in Cancer
8个月前
已完结
Dupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis
8个月前
已完结
345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis
8个月前
已完结
Biological therapies for pediatric atopic dermatitis – a review
9个月前
已完结
皖公网安备34019202002308
